The 340B Drug Pricing Program– a federal initiative designed to provide medications to lower income patients at reduced prices–is being manipulated by large health care entities in order to reap tens of billions of dollars in profits with little to no oversight and transparency. As a result, the intended beneficiaries- low-income patients- are being forced to pay full price for medications they cannot afford.

National Consumers League CEO Sally Greenberg speaks with Amy Hinojosa, President and CEO of Mana, a National Latina Organization, and Dr. Ge Bai, an expert on health care accounting, finance, and policy at Johns Hopkins University, regarding a shocking lack of transparency for a program that has more than doubled in cost reaching more than $120 Billion in 2022.